niacinamide has been researched along with Depression in 30 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
Excerpt | Relevance | Reference |
---|---|---|
"Depression is the leading cause of mental health-related disease globally, and it affects an estimated 300 million people worldwide." | 5.51 | Antidepressant activity of crocin-I is associated with amelioration of neuroinflammation and attenuates oxidative damage induced by corticosterone in mice. ( Fu, Z; Shen, Q; Wang, L; Xiao, Q; Xie, X; Xiong, Z; Yu, C; Zhou, J, 2019) |
" No previous study has, however, designated the time of TRP dosing to improve mood." | 2.90 | Effect of Tryptophan, Vitamin B ( Akamatsu, Y; Hayashi, T; Moritani, T; Nishida, MM; Tsujita, N, 2019) |
"Depression is one of the most common psychiatric disorders, and there is strong demand for developing novel antidepressants with better efficacy and less adverse effects." | 1.62 | Antidepressant-like effects of 1-methylnicotinamide in a chronic unpredictable mild stress model of depression. ( Gu, JH; Ji, CH; Jiang, B; Liu, Y; Tang, WQ; Zhang, Y; Zhao, J, 2021) |
"Depression is the leading cause of mental health-related disease globally, and it affects an estimated 300 million people worldwide." | 1.51 | Antidepressant activity of crocin-I is associated with amelioration of neuroinflammation and attenuates oxidative damage induced by corticosterone in mice. ( Fu, Z; Shen, Q; Wang, L; Xiao, Q; Xie, X; Xiong, Z; Yu, C; Zhou, J, 2019) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 15 (50.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (6.67) | 29.6817 |
2010's | 8 (26.67) | 24.3611 |
2020's | 5 (16.67) | 2.80 |
Authors | Studies |
---|---|
Wu, W | 1 |
Bours, MJL | 1 |
Koole, A | 1 |
Kenkhuis, MF | 1 |
Eussen, SJPM | 1 |
Breukink, SO | 1 |
van Schooten, FJ | 1 |
Weijenberg, MP | 1 |
Hageman, GJ | 1 |
Xiao, Q | 1 |
Xiong, Z | 1 |
Yu, C | 1 |
Zhou, J | 1 |
Shen, Q | 1 |
Wang, L | 1 |
Xie, X | 1 |
Fu, Z | 1 |
Jiang, Y | 1 |
Liu, Y | 2 |
Gao, M | 1 |
Xue, M | 1 |
Wang, Z | 1 |
Liang, H | 1 |
Tsujita, N | 1 |
Akamatsu, Y | 1 |
Nishida, MM | 1 |
Hayashi, T | 1 |
Moritani, T | 1 |
Liu, Z | 1 |
Li, C | 1 |
Fan, X | 1 |
Kuang, Y | 1 |
Zhang, X | 1 |
Chen, L | 1 |
Song, J | 1 |
Zhou, Y | 1 |
Takahashi, E | 1 |
He, G | 1 |
Li, W | 1 |
Zhao, J | 1 |
Zhang, Y | 1 |
Tang, WQ | 1 |
Ji, CH | 1 |
Gu, JH | 1 |
Jiang, B | 1 |
Willyard, C | 1 |
Bhattacharya, A | 1 |
Wang, Q | 1 |
Ao, H | 1 |
Shoblock, JR | 1 |
Lord, B | 1 |
Aluisio, L | 1 |
Fraser, I | 1 |
Nepomuceno, D | 1 |
Neff, RA | 1 |
Welty, N | 1 |
Lovenberg, TW | 1 |
Bonaventure, P | 1 |
Wickenden, AD | 1 |
Letavic, MA | 1 |
Gudkova, AN | 1 |
Osinovskaia, NA | 1 |
Polunina, AG | 1 |
Gekht, AB | 1 |
Belova, LA | 1 |
Mashin, VV | 1 |
Kolotik-Kameneva, OY | 1 |
Belova, NV | 1 |
Lethbridge, NL | 1 |
Chazot, PL | 1 |
Lepow, L | 1 |
Luckenbaugh, DA | 1 |
Park, L | 1 |
Henter, ID | 1 |
Zarate, CA | 1 |
Kats-Ugurlu, G | 1 |
Maass, C | 1 |
van Herpen, C | 1 |
de Waal, R | 1 |
Oosterwijk, E | 1 |
Mulders, P | 1 |
Hulsbergen-van de Kaa, C | 1 |
Leenders, W | 1 |
Rex, A | 1 |
Schickert, R | 1 |
Fink, H | 1 |
Chichakli, H | 1 |
Frosch, PJ | 1 |
Brinkmeier, T | 1 |
Young, SN | 5 |
Chouinard, G | 5 |
Annable, L | 5 |
Mys'ko, GN | 1 |
Fernando, JC | 1 |
Joseph, MH | 1 |
Curzon, G | 1 |
MacSweeney, DA | 1 |
Badawy, AA | 2 |
Evans, M | 2 |
Sourkes, TL | 4 |
Cazzullo, CL | 1 |
Sacchetti, E | 1 |
Smeraldi, E | 1 |
Kiriakos, RZ | 1 |
Stern, FH | 1 |
Schmitz, W | 1 |
Mangoni, A | 1 |
Green, RG | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Nicotinamide Riboside in Ulcerative Colitis[NCT05561738] | 40 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | |||
An Investigation of the Antidepressant Efficacy of Memantine, an NMDA Antagonist With Neurotrophic Properties in Major Depression[NCT00040261] | Phase 3 | 112 participants | Interventional | 2002-06-30 | Completed | ||
Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist[NCT00088699] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2004-07-26 | Completed | ||
An Investigation of the Antidepressant Effects of an NMDA Antagonist in Treatment-Resistant Major Depression[NCT00986479] | Phase 2 | 22 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Baseline
Intervention | units on a scale (Mean) |
---|---|
Ketamine - Healthy Volunteers | 1.17 |
Placebo - Healthy Volunteers | 1.48 |
Ketamine - MDD Patients | 33.83 |
Placebo - MDD Patients | 31.82 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Day 1
Intervention | units on a scale (Mean) |
---|---|
Ketamine - Healthy Volunteers | 2.45 |
Placebo - Healthy Volunteers | 0.67 |
Ketamine - MDD Patients | 23.73 |
Placebo - MDD Patients | 30.68 |
Beck Depression Inventory (BDI) is a 21-question instrument for measuring the severity of depression. Each question has a set of at least four possible answer choices, ranging in intensity. A value of 0 to 3 is assigned for each answer and the total score is computed. Higher total scores indicate more severe depressive symptoms. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
Intervention | Units on a scale (Least Squares Mean) | |||||||
---|---|---|---|---|---|---|---|---|
60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
AZD6765 (150 mg) | 21.081 | 22.217 | 21.535 | 21.126 | 22.444 | 22.923 | 23.494 | 24.447 |
Placebo | 22.886 | 23.122 | 23.586 | 23.686 | 22.936 | 24.586 | 23.786 | 24.070 |
Brief Psychiatric Rating Scale (BPRS) Positive is a 4-item scale which measures positive symptoms of schizophrenia (conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content). Each item is rated from 1 to 7 with higher score indicating greater severity. The total score is the sum of the 4 items, resulting in a range of scores from 4-28. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
Intervention | Units on a scale (Least Squares Mean) | |||||||
---|---|---|---|---|---|---|---|---|
60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
AZD6765 (150 mg) | 9.433 | 8.751 | 8.660 | 8.751 | 9.114 | 9.118 | 9.118 | 9.356 |
Placebo | 8.946 | 8.996 | 8.996 | 8.666 | 9.296 | 9.296 | 9.446 | 9.338 |
"The Brief Psychiatric Rating Scale (BPRS) is a 18-item scale which measures symptoms and behaviors that are characteristic of schizophrenia. Each item is rated from 1 to 7 with higher score indicating greater severity. The total score is the sum of the 18 items, resulting in a range of scores from 18-126.~18 is considered to be the best outcome, 126 the worst." (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
Intervention | Units on a scale (Least Squares Mean) | |||||||
---|---|---|---|---|---|---|---|---|
60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
AZD6765 (150 mg) | 32.191 | 30.237 | 30.555 | 30.737 | 33.418 | 32.882 | 34.168 | 35.739 |
Placebo | 32.896 | 33.496 | 33.696 | 31.772 | 33.596 | 34.496 | 33.046 | 34.428 |
Clinician- Administered Dissociative States Scale (CADSS) is a clinician-administered measure of perceptual, behavioral, and attentional alterations occurring during dissociative experiences. This scale involves a 23 questions and each is rated from 0 (not at all) to 4 (extremely). The total score is sum of the 23 items and range from 0 to 92 - best is 0 and worst is 92. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing
Intervention | Units on a scale (Least Squares Mean) | |||||||
---|---|---|---|---|---|---|---|---|
60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
AZD6765 (150 mg) | 4.104 | 3.324 | 2.831 | 1.240 | 1.013 | 1.360 | 1.456 | 1.313 |
Placebo | 1.997 | 2.297 | 2.047 | 1.497 | 1.147 | 1.397 | 1.447 | 1.212 |
Hamilton Anxiety Rating Scale (HAM-A) is used as a rating measure of anxiety severity. The scale consists of 14 items. Each item is rated on a scale of 0 to 4. The HAM-A total score is the sum of the 14 items and the score ranges from 0 to 56. 0 is considered the best outcome, 56 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
Intervention | Units on a scale (Least Squares Mean) | ||||
---|---|---|---|---|---|
230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
AZD6765 (150 mg) | 16.211 | 16.666 | 16.817 | 17.055 | 18.817 |
Placebo | 17.160 | 17.675 | 18.125 | 18.525 | 19.631 |
Hamilton Depression Rating Scale-17 item (HDRS) is a scale that assesses depressive symptoms. HDRS consists of 17 symptoms, each of which is rated from 0 to 2 or 0 to 4, where 0 is none/absent. The total score is calculated as the sum of the 17 individual symptom scores; the total score can range from 0 to 52. Higher scores indicate more severe depression. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing
Intervention | Units on a scale (Least Squares Mean) | |||||||
---|---|---|---|---|---|---|---|---|
60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
AZD6765 (150 mg) | 15.930 | 14.975 | 15.475 | 16.112 | 16.748 | 16.732 | 17.732 | 18.160 |
Placebo | 17.389 | 17.739 | 18.039 | 17.339 | 17.639 | 19.289 | 19.039 | 19.438 |
Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item instrument used for the evaluation of depressive symptoms. Each item is rated on a scale of 0 to 6 (with higher scores indicating more severe depression). The individual item scores are added together to form a total score, ranging between 0 and 60. 0 is considered the best score, 60 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
Intervention | Units on a scale (Least Squares Mean) | |||||||
---|---|---|---|---|---|---|---|---|
60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
AZD6765 (150 mg) | 26.881 | 25.381 | 25.835 | 26.517 | 27.654 | 29.161 | 30.732 | 31.447 |
Placebo | 28.618 | 29.718 | 29.818 | 29.418 | 29.118 | 31.368 | 30.368 | 31.222 |
Scale for Suicide Ideation (SSI) is a 19-item scale designed to quantify the intensity of current conscious suicide ideation. Each item is rated on a scale of 0 to 2 (with higher scores indicating greater suicidal ideation). The individual item scores are added together to form a total score, ranging between 0 and 38. 0 is considered the best outcome, 38 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
Intervention | Units on a scale (Least Squares Mean) | |||||||
---|---|---|---|---|---|---|---|---|
60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
AZD6765 (150 mg) | 0.955 | 1.137 | 1.137 | 0.864 | 1.364 | 1.236 | 1.379 | 1.379 |
Placebo | 0.939 | 1.039 | 0.989 | 0.939 | 1.539 | 1.189 | 1.226 | 1.507 |
Response defined as a >= 50% reduction from baseline in MADRS total score. MADRS is a 10-item instrument used for the evaluation of depressive symptoms. Each item is rated on a scale of 0 to 6 (with higher scores indicating more severe depression). The individual item scores are added together to form a total score, ranging between 0 and 60. 0 is considered the best score, 60 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
Intervention | Participants (Number) | |||||||
---|---|---|---|---|---|---|---|---|
60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
AZD6765 (150 mg) | 5 | 6 | 4 | 4 | 3 | 1 | 1 | 1 |
Placebo | 3 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
Remission defined as a Montgomery-Asberg Depression Rating Scale (MADRS) total score <10. MADRS is a 10-item instrument used for the evaluation of depressive symptoms. Each item is rated on a scale of 0 to 6 (with higher scores indicating more severe depression). The individual item scores are added together to form a total score, ranging between 0 and 60. 0 is considered the best score, 60 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
Intervention | Participants (Number) | |||||||
---|---|---|---|---|---|---|---|---|
60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
AZD6765 (150 mg) | 2 | 4 | 4 | 2 | 2 | 1 | 1 | 1 |
Placebo | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
"The Visual Analog Scale (VAS) Anxious is a 0 to 100-mm self-administered scale where patients rate their mood between extreme sad (0-mm) and extreme happy (100-mm), with a median normal point." (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
Intervention | Units on a scale (Least Squares Mean) | |||||||
---|---|---|---|---|---|---|---|---|
60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
AZD6765 (150 mg) | 43.898 | 44.216 | 42.853 | 44.580 | 44.989 | 44.718 | 42.623 | 50.147 |
Placebo | 41.929 | 44.079 | 44.729 | 46.029 | 47.229 | 50.479 | 48.279 | 56.595 |
"The Visual Analog Scale (VAS) Depressed is a 0 to 100-mm self-administered scale where patients rate their mood between extreme sad (0-mm) and extreme happy (100-mm), with a median normal point." (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing
Intervention | Scores on a scale (Least Squares Mean) | |||||||
---|---|---|---|---|---|---|---|---|
60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
AZD6765 (150 mg) | 55.614 | 58.614 | 60.750 | 55.614 | 62.160 | 65.753 | 66.896 | 68.467 |
Placebo | 60.562 | 57.662 | 59.062 | 61.212 | 64.762 | 63.262 | 63.312 | 65.576 |
Young Mania Rating Scale (YMRS) consists of 11 items, rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe) or from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. 0 is considered to be the best outcome, 60 the worst. (NCT00986479)
Timeframe: 60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.
Intervention | Units on a scale (Least Squares Mean) | |||||||
---|---|---|---|---|---|---|---|---|
60 minutes | 80 minutes | 110 minutes | 230 minutes | Day 1 | Day 2 | Day 3 | Day 7 | |
AZD6765 (150 mg) | 4.294 | 3.748 | 3.475 | 3.748 | 3.748 | 3.699 | 4.270 | 4.366 |
Placebo | 3.626 | 3.526 | 3.526 | 3.526 | 3.326 | 3.676 | 3.476 | 4.339 |
7 trials available for niacinamide and Depression
Article | Year |
---|---|
Effect of Tryptophan, Vitamin B
Topics: Adolescent; Adult; Affect; Depression; Dietary Supplements; Double-Blind Method; Female; Heart Rate; | 2019 |
[Investigation of the effects of cytoflavin on symptoms of depression and autonomic dysfunction in patients with organic depressive disorder].
Topics: Adult; Antidepressive Agents; Autonomic Nervous System Diseases; Depression; Depressive Disorder; Dr | 2013 |
Letter: Treatment of unipolar depression.
Topics: Depression; Electroconvulsive Therapy; Female; Humans; Male; Middle Aged; Niacinamide; Tryptophan | 1975 |
Tryptophan-nicotinamide combination in depression.
Topics: Adult; Aged; Clinical Trials as Topic; Depression; Drug Synergism; Drug Therapy, Combination; Female | 1977 |
Tryptophan dosage critical for its antidepressant effect.
Topics: Clinical Trials as Topic; Depression; Double-Blind Method; Drug Synergism; Humans; Imipramine; Niaci | 1978 |
Tryptophan-nicotinamide, imipramine and their combination in depression. A controlled study.
Topics: Adult; Bipolar Disorder; Clinical Trials as Topic; Depression; Double-Blind Method; Drug Evaluation; | 1979 |
Long-term management of symptoms of cerebral arteriosclerosis.
Topics: Aged; Anxiety; Clinical Trials as Topic; Depression; Drug Synergism; Female; Humans; Intracranial Ar | 1971 |
23 other studies available for niacinamide and Depression
Article | Year |
---|---|
Cross-Sectional Associations between Dietary Daily Nicotinamide Intake and Patient-Reported Outcomes in Colorectal Cancer Survivors, 2 to 10 Years Post-Diagnosis.
Topics: Aged; Anxiety; Cancer Survivors; Cognition; Colorectal Neoplasms; Cross-Sectional Studies; Depressio | 2021 |
Antidepressant activity of crocin-I is associated with amelioration of neuroinflammation and attenuates oxidative damage induced by corticosterone in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Carotenoids; Corticosterone; Depression; Hippocamp | 2019 |
Nicotinamide riboside alleviates alcohol-induced depression-like behaviours in C57BL/6J mice by altering the intestinal microbiota associated with microglial activation and BDNF expression.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cytokines; Depression; Disease Models, Animal; Ethanol; | 2020 |
Nicotinamide, a vitamin B3 ameliorates depressive behaviors independent of SIRT1 activity in mice.
Topics: Adenosine Triphosphate; Animals; Antidepressive Agents; Behavior, Animal; Depression; Integrases; Ma | 2020 |
Antidepressant-like effects of 1-methylnicotinamide in a chronic unpredictable mild stress model of depression.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Chronic Disease; Depression; Dise | 2021 |
How gut microbes could drive brain disorders.
Topics: alpha-Synuclein; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Autism Spectrum Disorder | 2021 |
Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567.
Topics: Adenosine Triphosphate; Analgesics; Animals; Antidepressive Agents; Antimanic Agents; Behavior, Anim | 2013 |
[Effect of cytoflavin on the clinical and autonomic-psychological manifestations of hypertensive disease].
Topics: Adult; Aged; Antihypertensive Agents; Anxiety; Autonomic Nervous System Diseases; Cognition Disorder | 2016 |
Ligand autoradiographical quantification of histamine H
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Autoradiography; Benzazepines; Cerebellar Cortex; Dement | 2016 |
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum | 2017 |
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum | 2017 |
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum | 2017 |
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum | 2017 |
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum | 2017 |
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum | 2017 |
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum | 2017 |
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum | 2017 |
Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
Topics: Adamantane; Adult; Antidepressive Agents; Depression; Excitatory Amino Acid Antagonists; Female; Hum | 2017 |
Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production.
Topics: Antineoplastic Agents; Arthritis, Rheumatoid; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Tri | 2011 |
Antidepressant-like effect of nicotinamide adenine dinucleotide in the forced swim test in rats.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tri | 2004 |
[Symmetrical bullous acral erythema in a 58-year-old female alcoholic].
Topics: Administration, Oral; Alcoholism; Anti-Anxiety Agents; Biopsy; Depression; Diagnosis, Differential; | 2006 |
Tryptophan in the treatment of depression.
Topics: Allopurinol; Antidepressive Agents, Tricyclic; Ascorbic Acid; Bipolar Disorder; Depression; Electroc | 1981 |
[Several indices of the methylation process in schizophrenic patients].
Topics: Adult; Antipsychotic Agents; Automatism; Catechol O-Methyltransferase; Depression; Female; Hallucina | 1977 |
Letter: Tryptophan plus a pyrrolase inhibitor for depression?
Topics: Allopurinol; Brain; Depression; Drug Synergism; Drug Therapy, Combination; Humans; Niacinamide; Time | 1975 |
Letter: Tryptophan plus a pyrrolase inhibitor for depression.
Topics: Allopurinol; Animals; Depression; Drug Synergism; Drug Therapy, Combination; Glucose; Humans; Niacin | 1975 |
N-methylnicotinamide excretion and affective disorders.
Topics: Adjustment Disorders; Adolescent; Adult; Bipolar Disorder; Depression; Female; Humans; Male; Middle | 1976 |
Tryptophan-nicotinamide combination in the treatment of newly admitted depressed patients.
Topics: Adult; Bipolar Disorder; Depression; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; N | 1978 |
Letter: Tryptophan plus a pyrrolase inhibitor for depression?
Topics: Adult; Allopurinol; Animals; Depression; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; | 1974 |
[Psychopathology of pellagra in children].
Topics: Bipolar Disorder; Brain Damage, Chronic; Child; Depression; Electroencephalography; Hallucinations; | 1971 |
The "kynurenine shunt" and depression.
Topics: Adrenal Glands; Adrenalectomy; Amitriptyline; Animals; Antidepressive Agents; Depression; Humans; Im | 1974 |
Letter: Suicide and depression in childhood and adolescence.
Topics: Adolescent; Age Factors; Ascorbic Acid; Avitaminosis; Child; Depression; Humans; Niacinamide; Pellag | 1974 |